Aus 2002.

Methods	Randomised study examining the use of hormone therapy neo‐adjuvant to prostatectomy in the treatment of prostate cancer (stage T1b‐3a, Nx, M0) Quality Score (1/0/1)
Participants	Patients entered: 126 Patients evaluable: 111 Age (Mean): 67 Range: 50 ‐ 77 Eligibility Criteria: · Previously untreated prostate cancer · Histologically confirmed stage T1b‐3a, Nx, M0, G1‐3 · Aged = 75 years · Lifespan > 10 years · Diagnosis by histologically confirmed biopsies or TURP specimens Ineligibility Criteria: · Not Stated Exclusion Criteria: · 12 were excluded because of positive lymph nodes in frozen sections (9 in the control and 3 in the neo‐adjuvant group) · Another 3 patients not operated upon (1 moved abroad, 1 changed his mind in favour of radiotherapy, and 1 was disqualified from surgery owing to a newly detected aortic stenosis).
Interventions	Radical Prostatectomy alone Vs. 3 mths hormone treatment followed by Prostatectomy Evaluable: 55 Vs. 56 Hormone Therapy: 3 months of Triptorelin (Decapeptyl Depot) administered as intra‐muscular injections (3.75mg) every fourth week N.B. To prevent tumour flare Cyproterone acetate (Androcur) was given 1 week before and 2 weeks after the first Triptorelin injection.
Outcomes	i. Histological grading ii. Positive surgical margin status iii. Crude overall survival iv. PSA progression free survival
Notes	The main outcome of this study is surgical margins.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear